- Home
- TLSI vs MPA Comparison
TLSI vs MPA Comparison
Compare TLSI & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- MPA
- Stock Information
- Founded
- TLSI 2010
- MPA 1992
- Country
- TLSI United States
- MPA United States
- Employees
- TLSI N/A
- MPA N/A
- Industry
- TLSI Medical Specialities
- MPA Finance Companies
- Sector
- TLSI Health Care
- MPA Finance
- Exchange
- TLSI Nasdaq
- MPA Nasdaq
- Market Cap
- TLSI 244.3M
- MPA 148.2M
- IPO Year
- TLSI N/A
- MPA N/A
- Fundamental
- Price
- TLSI $4.74
- MPA $11.46
- Analyst Decision
- TLSI Strong Buy
- MPA
- Analyst Count
- TLSI 4
- MPA 0
- Target Price
- TLSI $11.13
- MPA N/A
- AVG Volume (30 Days)
- TLSI 128.5K
- MPA 25.2K
- Earning Date
- TLSI 11-13-2025
- MPA 01-01-0001
- Dividend Yield
- TLSI N/A
- MPA 3.83%
- EPS Growth
- TLSI N/A
- MPA N/A
- EPS
- TLSI N/A
- MPA N/A
- Revenue
- TLSI $35,990,000.00
- MPA N/A
- Revenue This Year
- TLSI $56.71
- MPA N/A
- Revenue Next Year
- TLSI $52.25
- MPA N/A
- P/E Ratio
- TLSI N/A
- MPA N/A
- Revenue Growth
- TLSI 45.50
- MPA N/A
- 52 Week Low
- TLSI $3.42
- MPA $9.87
- 52 Week High
- TLSI $5.88
- MPA $12.21
- Technical
- Relative Strength Index (RSI)
- TLSI 47.09
- MPA 59.79
- Support Level
- TLSI $4.57
- MPA $11.29
- Resistance Level
- TLSI $5.18
- MPA $11.50
- Average True Range (ATR)
- TLSI 0.23
- MPA 0.11
- MACD
- TLSI -0.02
- MPA -0.01
- Stochastic Oscillator
- TLSI 37.23
- MPA 68.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with an investment objective to provide shareholders with as high a level of current income exempt from U.S. federal and Pennsylvania income taxes as is consistent with its investment policies and prudent investment management. The Fund seeks to achieve its investment objective by investing, as a fundamental policy, at least 80% of an aggregate of the Fund's net assets and the proceeds of any borrowings for investment purposes, in a portfolio of municipal obligations issued by or on behalf of the State of Pennsylvania, its political subdivisions, agencies, and instrumentalities and by other qualifying issuers.